Berry Genomics released its 2026 semi-annual report, showing a net loss attributable to shareholders of about 43.95 million yuan in the first half, a year-on-year decline of 61.32%. The company achieved operating revenue of about 447 million yuan over the same period, down 0.15% year on year. Berry Genomics said the loss was mainly due to an increase in provisions for bad debts on accounts receivable and higher research and development expenses, with increased depreciation of R&D equipment and related spending driving overall R&D expense growth.
Berry Genomics Co LtdNet loss attributable to shareholders of 43.95 million yuan, down 61.32% year-on-year, due to higher bad debt provisions and R&D expenses.
